Skip to main content
logo
Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS · Delayed Price · Currency is USD
0.0350
+0.000835 (2.44%)
At close: Aug 11, 2026

Oncotelic Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
---0.07--
Revenue Growth
------
Gross Profit
---0.07--
Operating Income
-4.74-2.99-0.38-0.56-5.61-9.13
Net Income
247.38249.28-4.52-7.95.09-9.39
Earnings Per Share
0.580.59-0.01-0.020.01-0.03
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
0.060.090.090.170.240.57
Total Debt
14.3113.9113.0912.5711.268.99
Net Cash (Debt)
-14.25-13.82-13-12.4-11.02-8.42
Net Cash Growth
------
Net Cash Per Share
-0.03-0.03-0.03-0.03-0.02-0.03

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-1.56-1.38-0.74-1.32-1.45-4.43
Free Cash Flow
-1.56-1.38-0.74-1.32-1.45-4.43
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
---100.00%--
Operating Margin
----806.96%--
Pretax Margin
----11722.95%--
Profit Margin
----11290.13%--

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
0.060.15--3.45-
PS Ratio
---218.13--